Clinical Trial

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Study acronym: REMASTER
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
Protocol Amendment History 11 changes
notable Trial sites expanded: 236 -> 256 locations 2026-07-30
notable Trial sites expanded: 223 -> 236 locations 2026-07-14
notable Trial sites expanded: 208 -> 223 locations 2026-06-24
notable Trial sites expanded: 200 -> 208 locations 2026-06-02
notable Trial sites expanded: 187 -> 200 locations 2026-05-28
notable Trial sites expanded: 180 -> 187 locations 2026-05-20
notable Trial sites expanded: 164 -> 180 locations 2026-05-13
notable Trial sites expanded: 136 -> 164 locations 2026-05-05
notable Trial sites expanded: 90 -> 136 locations 2026-04-25
notable Trial sites expanded: 61 -> 90 locations 2026-04-07
notable Trial sites expanded: 44 -> 61 locations 2026-03-27
Trial Details
NCT Number NCT07225504
Lead Sponsor Novartis Pharmaceuticals
Conditions Secondary Progressive Multiple Sclerosis (SPMS)
Enrollment 1,275 participants
Start Date 2025-11-11
Primary Completion 2030-12-03 (estimated)
Study Completion 2034-01-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-29